Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*)
- PMID: 21251183
- PMCID: PMC3070963
- DOI: 10.1111/j.1468-1293.2010.00901.x
Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*)
Abstract
Objectives: The aim of the study was to estimate the rates of cardiovascular disease (CVD) events after stopping smoking in patients with HIV infection.
Methods: Patients who reported smoking status and no previous CVD prior to enrolment in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were included in this study. Smoking status is collected at each visit as current smoker (yes/no) and ever smoker (yes/no). Time since stopping smoking was calculated for persons who had reported current smoking during follow-up and no current smoking subsequently. Endpoints were: myocardial infarction (MI); coronary heart disease (CHD: MI plus invasive coronary artery procedure or death from other CHD); CVD (CHD plus carotid artery endarterectomy or stroke); and all-cause mortality. Event rates were calculated for never, previous and current smokers, and smokers who stopped during follow-up. Incidence rate ratios (IRRs) were determined using Poisson regression adjusted for age, sex, cohort, calendar year, family history of CVD, diabetes, lipids, blood pressure and antiretroviral treatment.
Results: A total of 27 136 patients had smoking status reported, with totals of 432, 600, 746 and 1902 MI, CHD, CVD and mortality events, respectively. The adjusted IRR of CVD in patients who stopped smoking during follow-up decreased from 2.32 within the first year of stopping to 1.49 after >3 years compared with those who never smoked. Similar trends were observed for the MI and CHD endpoints. Reductions in risk were less pronounced for all-cause mortality.
Conclusion: The risk of CVD events in HIV-positive patients decreased with increasing time since stopping smoking. Smoking cessation efforts should be a priority in the management of HIV-positive patients.
© 2011 British HIV Association.
Figures
Similar articles
-
Smoking cessation for secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936. doi: 10.1002/14651858.CD014936.pub2. Cochrane Database Syst Rev. 2022. PMID: 35938889 Free PMC article. Review.
-
Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Clin Infect Dis. 2019 Feb 1;68(4):650-657. doi: 10.1093/cid/ciy508. Clin Infect Dis. 2019. PMID: 29912335
-
Smoking and projected cardiovascular risk in an HIV-positive Asian regional cohort.HIV Med. 2016 Aug;17(7):542-9. doi: 10.1111/hiv.12358. HIV Med. 2016. PMID: 27430354 Free PMC article.
-
Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies.Lancet. 2015 Oct 10;386(10002):1447-56. doi: 10.1016/S0140-6736(15)00340-2. Lancet. 2015. PMID: 26466050 Free PMC article. Review.
-
An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.Eur J Prev Cardiol. 2016 Jan;23(2):214-23. doi: 10.1177/2047487315579291. Epub 2015 Apr 16. Eur J Prev Cardiol. 2016. PMID: 25882821
Cited by
-
Tobacco Smoking and Pack-Years Are Associated With Frailty Among People With HIV.J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):135-142. doi: 10.1097/QAI.0000000000003242. J Acquir Immune Defic Syndr. 2023. PMID: 37368939
-
Practices, attitudes, and confidence related to tobacco treatment interventions in HIV clinics: a multisite cross-sectional survey.Transl Behav Med. 2022 Jul 7;12(6):726-733. doi: 10.1093/tbm/ibac022. Transl Behav Med. 2022. PMID: 35608982 Free PMC article.
-
Tobacco Use and Treatment of Tobacco Dependence Among People With Human Immunodeficiency Virus: A Practical Guide for Clinicians.Clin Infect Dis. 2022 Aug 31;75(3):525-533. doi: 10.1093/cid/ciab1069. Clin Infect Dis. 2022. PMID: 34979543 Free PMC article.
-
Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy.Front Immunol. 2021 Jan 29;11:594110. doi: 10.3389/fimmu.2020.594110. eCollection 2020. Front Immunol. 2021. PMID: 33584658 Free PMC article.
-
Self-control and smoking in a sample of adults living with HIV/AIDS: A cross-sectional survey.Addict Behav. 2021 May;116:106807. doi: 10.1016/j.addbeh.2020.106807. Epub 2020 Dec 29. Addict Behav. 2021. PMID: 33460989 Free PMC article.
References
-
- Grierson J, Thorpe R, Saunders M, Pitts M. HIV Futures4: state of the [positive] nation, monograph series number 48. Melbourne Australia: The Australian Research Centre in Sex, Health and Society, Latrobe University; 2004.
-
- Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS. 2007;21:458–468. - PubMed
-
- Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking Among HIV Positive New Yorkers: Prevalence, Frequency, and Opportunities for Cessation. AIDS Behav. 2008 - PubMed
-
- Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS. 2002;16:39–42. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical